BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2019 9:34:50 AM | Browse: 1464 | Download: 2653
Publication Name World Journal of Gastroenterology
Manuscript ID 47108
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells
Manuscript Source Unsolicited Manuscript
All Author List Shun-Zhen Zheng, Ping Sun, Jian-Ping Wang, Yong Liu, Wei Gong and Jun Liu
ORCID
Author(s) ORCID Number
Shun-Zhen Zheng http://orcid.org/0000-0002-3028-3430
Ping Sun http://orcid.org/0000-0003-3006-7647
Jian-Ping Wang http://orcid.org/0000-0001-9683-7689
Yong Liu http://orcid.org/0000-0002-5229-507X
Wei Gong http://orcid.org/0000-0001-5930-7160
Jun Liu http://orcid.org/0000-0003-4707-7286
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 81302124
Shandong Key R&D Program 2017GSF218038
Shandong Provincial Natural Science Foundation ZR2014HP065
Corresponding Author Jun Liu, MD, Professor, Surgeon, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun1967@126.com
Key Words MiR-34a; Doxorubicin; Hepatocellular carcinoma; HepG2 cells; Growth inhibition
Core Tip Hepatocellular carcinoma (HCC) is the third leading cause of death from malignant tumors worldwide. The prognosis remains poor and the overall efficacy is still unsatisfactory. Chemotherapy resistance is the most important reason for the poor outcome of HCC. We found that upregulation of miR-34a can increase the chemosensitivity of HCC cells to doxorubicin. MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating multidrug resistance protein 1/P glycoprotein and AXL, which may be related to expression of p53.
Publish Date 2019-06-14 09:34
Citation Zheng SZ, Sun P, Wang JP, Liu Y, Gong W, Liu J. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol 2019; 25(22): 2752-2762
URL https://www.wjgnet.com/1007-9327/full/v25/i22/2752.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i22.2752
Full Article (PDF) WJG-25-2752.pdf
Full Article (Word) WJG-25-2752.docx